This trial has been completed.

Condition glioblastoma
Treatments bevacizumab, radiation therapy
Phase phase 2
Target VEGF
Sponsor University of Zurich
Start date October 2011
End date August 2015
Trial size 75 participants
Trial identifier NCT01443676, ARTE


The purpose of this study is to explore the efficacy of bevacizumab combined with radiotherapy compared with radiotherapy alone in the treatment of newly diagnosed glioblastoma in the elderly.

- Trial with medicinal product

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
radiation therapy
Radiation therapy
Radiotherapy plus Bevacizumab
bevacizumab Avastin
Bevacizumab will be added to radiotherapy

Primary Outcomes

median overall survival
time frame: 1 year

Secondary Outcomes

progression-free survival
time frame: progression-free survival after 6 months

Eligibility Criteria

Male or female participants at least 65 years old.

Inclusion criteria: Diagnosis: newly diagnosed glioblastoma in elderly patients 1. Signed informed consent 2. Age > 65 years 3. Newly diagnosed supratentorial glioblastoma 4. Eligible for first infusion of bevacizumab > 28 and > 49 days after surgery for glioblastoma 5. Karnofsky performance score 60 or more 6. Paraffin-embedded tissue for central pathology review 7. Stable or decreasing corticosteroid dose within 5 days prior to enrolment 8. Adequate haematological function: 9. Adequate liver function 10. Adequate renal function Exclusion criteria: 1. Karnofsky performance score 50 or less 2. Evidence of recent hemorrhage on postoperative brain MRI 3. Tumor with infiltration of retina, optic nerve, optic chiasm or brainstem 4. Any prior chemotherapy including carmustine-containing wafers (Gliadel®) or immunotherapy for glioblastoma or lower grade astrocytomas 5. Any prior radiotherapy to the brain or prior radiotherapy resulting in a potential overlap in the radiation field 6. Inadequately controlled hypertension 7. History of hypertensive crisis or hypertensive encephalopathy 8. New York Heart Association (NYHA) grade II or higher congestive heart failure 9. Myocardial infarction or unstable angina within 6 months prior to enrolment 10. Stroke or transitory ischemic attack within 6 months prior to enrolment 11. Other significant vascular disease within 6 months prior to enrolment 12. History of = grade 2 haemoptysis within 1 month prior to enrolment 13. Bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation 14. Major surgical procedure, open biopsy, intracranial biopsy, ventriculoperitoneal shunt or significant traumatic injury within 28 days prior to first dose of bevacizumab 15. Core biopsy (excluding intracranial biopsy) or other minor surgical procedure within 7 days prior to first dose of bevacizumab 16. Abdominal fistula or gastrointestinal perforation within 6 months prior to enrolment 17. Intracranial abscess within 6 months prior to enrolment 18. Serious non-healing wound, active ulcer or untreated bone fracture 19. Pregnancy or lactation 20. Fertile women < 2 years after last menstruation and men unwilling or unable to use effective means of contraception 21. Active malignancy that may interfere with the study treatment at the investigator?s and PI discretion

Additional Information

Official title Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma
Principal investigator Michael Weller, Professor
Description This is a randomized (2:1), explorative, parallel-group, open-label, phase II trial in elderly patients with newly diagnosed glioblastoma. In the control arm, patients will receive radiotherapy, in the experimental arm, patients will receive bevacizumab during and after radiotherapy until progression. Background: For decades, neurosurgical resection and postoperative radiotherapy have been the cornerstones of treatment for patients with glioblastoma. Most chemotherapeutic agents showed little or no activity in malignant glioma patients, with the possible exception of nitrosoureas. This has changed with the introduction of temozolomide, first shown to be active in recurrent disease (Yung et al. 2000) and more recently in newly diagnosed glioblastoma (Stupp et al. 2005, 2009). This EORTC 26981-22981 NCIC CE.3 trial demonstrated an increase in median survival from 12.1 to 14.6 months and of the 2 year survival rate from 10% to 26% in patients receiving radiotherapy plus temozolomide compared with radiotherapy alone. Notably patients with tumors exhibiting methylation of the promoter region of the O6-methylguanine DNA methyltransferase (MGMT) gene showed a striking benefit from temozolomide (Hegi et al. 2005). Yet, inclusion in this trial was limited to patients up to the age of 70, and subgroup analyses demonstrated that younger patients were more likely to derive benefit from combined modality treatment than older patients. Thus, radiotherapy alone is still the standard of care in the elderly. The value of radiotherapy has been confirmed in a small randomized trial comparing best supportive care versus radiotherapy alone: median survival was 29 weeks with radiotherapy compared with 16.9 weeks with supportive care only (Keime-Guibert et al. 2007). Based on the overall shorter survival in elderly patients, hypofractionated radiotherapy has been explored and shown to be equieffective in patients aged 65-70 years and more (Roa et al. 2004). Two randomized trials presented in abstract form at the Annual Meeting of the American Society of Clinical Oncology in June 2010 failed to show superiority of primary temozolomide chemotherapy alone over radiotherapy alone in elderly patients (Malmstrom et al. 2010, Wick et al. 2010a). In fact, the German NOA-08 trial even showed that primary temozolomide alone is not non-inferior to primary radiotherapy alone (Wick et al. 2010a). A concomitant treatment strategy is currently evaluated in a NCIC-EORTC randomized trial. Further, the Nordic trial corroborated the equieffectiveness of an accelerated radiotherapy protocol of 40 Gy administered in 15 fractions versus the standard fractionation of 30 x 2 Gy. Altogether, these clinical data justify the exploration of new, temozolomide-free first-line treatment strategies in glioblastoma. Glioblastomas express high levels of vascular endothelial growth factor (VEGF) and are highly vascularized tumors. The VEGF antibody, bevacizumab, has recently gained approval in patients with recurrent glioblastoma in the USA and in Switzerland in 2009, but not in the EU. Its role in the first-line treatment of glioblastoma is currently being evaluated in randomized trials. There is limited data on the safety and efficacy of bevacizumab in elderly patients with glioblastoma, although the safety profile of bevacizumab in elderly patients with other types of cancer, e.g., lung cancer is favorable. There are ample rationales for combining bevacizumab with radiotherapy, including the induction of VEGF by radiotherapy and the concept of vascular normalization resulting in increased oxygenation and thus sensitivity to radiotherapy. Thus, bevacizumab is not only expected to inhibit angiogenesis, but may also exhibit additive or synergistic interactions with radiotherapy and further impair tumor growth. Altogether, this study seeks to explore, using a dedicated neuroimaging protocol, the possibility that bevacizumab enhances the effects of radiotherapy via the process of vascular normalization. The purpose of this study is to explore the efficacy of bevacizumab combined with radiotherapy compared with radiotherapy alone in the treatment of newly diagnosed glioblastoma in the elderly.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by University of Zurich.